Late Breaking Abstract: Comparison of bioavailability of two zanamivir inhalation powder formulations in healthy subjects

S. Chachad, P. Bsb, A. Gomes, M. Gole, S. Purandare, G. Malhotra, A. Lulla (Mumbai, India)

Source: Annual Congress 2010 - From viral bronchiolitis to recurrent pneumonia in childhood: diagnosis, treatment and underlying factors
Disease area: Paediatric lung diseases, Respiratory infections

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
S. Chachad, P. Bsb, A. Gomes, M. Gole, S. Purandare, G. Malhotra, A. Lulla (Mumbai, India). Late Breaking Abstract: Comparison of bioavailability of two zanamivir inhalation powder formulations in healthy subjects. Eur Respir J 2010; 36: Suppl. 54, 3459

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Comparison of systemic bioavailability of two formulations of budesonide nebulized suspension in healthy subjects
Source: Annual Congress 2009 - New aspects of inhalation therapy
Year: 2009

Intrapulmonary pharmacokinetics of laninamivir in healthy subjects: Comparison between a nebulizer and a dry powder inhaler
Source: International Congress 2018 – New therapies for respiratory infections: experimental and translational studies
Year: 2018




Salmeterol pharmacokinetics following a 50-mcg dose by dry powder oral inhalation to healthy volunteers
Source: Annual Congress 2012 - Phenotypes and mechanisms of treatment of asthma
Year: 2012


Late Breaking Abstract - Pharmacokinetic and pharmacodynamic interactions between components of extrafine formulation of BDP/FF/GB, a novel fixed-dose triple combination for asthma and COPD
Source: International Congress 2018 – COPD: from LABA/ICS to LABA/LAMA/ICS
Year: 2018



Dry powder inhaled ribavirin in healthy volunteers:  safety, tolerability, lung and systemic pharmacokinetics
Source: International Congress 2017 – From microbiology to clinical work
Year: 2017


Late Breaking Abstract - Ability of Hong Kong COPD patients to inhale dry powder inhaler
Source: International Congress 2019 – Advances in COPD pharmacology
Year: 2019


Assessment of usability of a novel multi-dose dry powder inhaler in healthy volunteers and mild asthmatics
Source: Eur Respir J 2007; 30: Suppl. 51, 70s
Year: 2007

Comparison of pulmonary and systemic absoption of two HFA formulations of salmeterol in healthy subjects
Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II
Year: 2010

Pharmacokinetics and pharmacodynamics of ciclesonide and its active principle after inhalative and intravenous administration in healthy subjects
Source: Eur Respir J 2002; 20: Suppl. 38, 110s
Year: 2002

Safety and pharmacokinetics of multiple-dose ciprofloxacin dry powder for inhalation in patients with moderate or severe COPD
Source: Annual Congress 2011 - Role of infection in exacerbations of COPD
Year: 2011

Pharmacokinetics (PK) of indacaterol acetate and mometasone furoate delivered alone or in combination following once daily inhalation in healthy subjects
Source: International Congress 2014 – Asthma and COPD management
Year: 2014


Pharmacokinetics (PK) of mometasone furoate and indacaterol in Japanese and Caucasian healthy subjects after once daily inhalation of QMF149
Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics
Year: 2013

Late Breaking Abstract - Short-term and maintenance oral corticosteroid use for German patients with asthma
Source: International Congress 2019 – Powerful cohort studies with/without lung function
Year: 2019



Effects and modulation of release rate of inhaled ciprofloxacin with liposomal formulations in healthy subjects and patients with bronchiectasis
Source: Annual Congress 2010 - New aspects of treatment of lower respiratory tract infections
Year: 2010

Evaluation of safety, tolerability, pharmacokinetics, and food effect of Danirixin oral tablets in Japanese elderly healthy subjects
Source: International Congress 2018 – Integrating pharmacological and non-pharmacological management in COPD: are we there yet?
Year: 2018




Efficacy and safety profile of doxofylline compared to theophylline in asthma: a meta-analysis
Source: International Congress 2019 – Asthma: outcomes of clinical trials and cohorts
Year: 2019

Comparison of the release characteristics of formoterol dihydrate powder for inhalation delivered through two different types of multidose dry powder inhalers (MDPI)
Source: Eur Respir J 2005; 26: Suppl. 49, 126s
Year: 2005

Safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of GSK573719 inhalation powder in healthy subjects
Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II
Year: 2011

Late Breaking Abstract - Comparing pneumonia risk in COPD patients initiating Fixed Dose Combination (FDC) inhaler comprising extrafine beclometasone dipropionate versus fluticasone
Source: Virtual Congress 2021 – COPD pharmacology: from basic science to real-world data
Year: 2021



Late Breaking Abstract - Factors associated with health-status of COPD patients on Dry Powder Inhaler (DPI) maintenance therapy
Source: Virtual Congress 2021 – Highlights for primary care in 2021
Year: 2021